Single Dose Radiotherapy Services Market Driven by Reduced Operational Costs and Side Effects

Increasing investments into cancer research favorable changes to healthcare and reimbursement policies are major factors supporting developments for single dose radiotherapy treatments. The single dose radiotherapy service market is expected to reflect a healthy growth rate of over 6% CAGR from 2021 to 2031. Growing awareness among men about the risks of prostate cancer will influence developments in the market in the near future. Lower risk of side effects among geriatrics supports adoption of this health care offering.

“In recent years, the single-dose radiotherapy services market has gained from major technological advancements in cancer research. These innovations have aided in the improvements to low-cost, effective, and convenient radiotherapy products with high levels of accuracy in radiation dose delivery to boost increased efficiency in targeting tumors,” says the FMI study.

For more insights into the Market, Request a Sample of this Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-13033

Single Dose Radiotherapy Services Market – Primary Takeaways

• Breast cancer treatment accounts for a larger market share owing to its high prevalence, especially in female demographics.
• Specialized centers for radiotherapy emerge as the leading users owing to capital expenses on new technologies in the field.
• Poor lifestyles and resultant increase in cancer cases in a vast population are generating opportunities in China.
• Government investments with advancements in automation for cancer treatments makes UK a high potential market.

Single Dose Radiotherapy Services Market – Growth Factors

• Widespread global prevalence of breast cancer is a major driver for single dose radiotherapy treatments.
• Government and non-profit programs towards cancer awareness and research are contributing to growth opportunities.
• Benefits of reduced toxicity and fractionation in terms of convenience for patients supports market prospects.

Single Dose Radiotherapy Services Market – Major Constraints

• Shortage of adequately skilled professionals is a challenge to adoption rates in the market.
• Lack of awareness among patients about single dose radiotherapy is an obstacle to growth.

For any Queries Linked with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-13033

Expected Impact on Market by Coronavirus Outbreak

The covid-19 pandemic has negatively affected developments in the global single dose radiotherapy service market. Lockdown restrictions and social distancing guidelines have limited public access to elective medical procedures which hurt demand in the short term. Also, redirection of healthcare resources towards handling the pandemic has resulted in delays for procedures and devices sales hurting market players.

The market is anticipated to display a steady recovery through 2021 accounted for by the large number of cancer cases around the world, and the backlog of treatments arising from the covid-19 crisis. Continued efforts towards awareness about breast cancer especially among women will also generate revenue growth opportunities, supporting long-term development in the sector.

Competition Landscape

Prominent manufacturers operating in the single dose radiotherapy services market include but are not limited to Panacea Medical Technologies, Varian Medical Systems, Mevion Medical Systems, Accuray, Provision Healthcare, Elekta, Hitachi, Ion Beam Applications, ViewRay, and IsoRay Medical.

Major players in the single dose radiotherapy services market are focusing on research and development initiatives with strategic industry collaborations aimed towards tech and service improvements for sustainable, long-term revenue streams.

In March 2021, the Miami Cancer Institute collaborated with Baptist Health’s Miami Cardiac & Vascular Institute to perform the first stereotactic body radiation therapy procedure, which does not require hospitalization or anesthesia. Further, Actinium Pharmaceuticals Inc. announced initial patient enrollment for the clinical trial Actimab-A venetoclax aimed for acute myeloid leukemia treatments. Also, Sirtex Medical announced FDA approval for clinical trial of DOORwaY90 to test the efficacy and safety of selective internal radiation therapy (SIRT) for patients with unresectable hepatocellular carcinoma (HCC).

Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/13033

Explore Wide-ranging Coverage of FMI’s Healthcare Landscape

Onychomycosis Treatment Market: Find insights on the onychomycosis treatment market with analysis of statistics, segments, players, influencers, and business strategies adopted over a 10-year forecast period.

China First Aid Market: FMI’s report on the China first aid market provides insights on the market for 2014-2020. The study evaluates restraining forces, revenue sources, market leaders, and market strategies.

Surgical Generators Market: An analysis on the surgical generators market with data on opportunities, growth levers, regional markets, restraints, regulatory policies, and strengths of market leaders.

About FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com